[关键词]
[摘要]
眼底新生血管性疾病(FNDs)是一种由于眼底血管病理性改变引起的眼部疾病，是全球导致视力损害的主要病因。血管内皮生长因子(VEGF)的过度表达在新生血管的形成中起重要作用，目前FNDs的一线治疗是应用抗VEGF药物。眼睛具有特殊的血-眼屏障，滴眼、口服或者静脉使用药物均很难进入眼内发挥作用，眼内注射可以绕开该屏障，将药物直接注射到眼内，是治疗眼部疾病的主要给药途径。与全身给药相比，其更利于药物在靶部位富集并能减少全身不良反应，包括局部玻璃体内注射(IVI)、脉络膜上腔(SCS)注射、视网膜下注射(SRI)、药物缓释系统等。已有研究表明不同的眼内给药方式会影响药物的药代动力学(PK)特性。文章对抗VEGF药物在不同眼内给药方式下的药物代谢动力学变化进行综述。
[Key word]
[Abstract]
Fundus neovascular diseases(FNDs)are ocular diseases caused by pathological changes in retinal blood vessels, which are the leading cause of visual impairment globally. The overexpression of vascular endothelial growth factor(VEGF)plays an important role in the formation of new blood vessels, and the current first-line treatment for FNDs is anti-VEGF drugs. The eyes have a special blood-eye barrier, which makes it difficult for eye drops, oral or intravenous drugs to enter the eye and exert their effects. Intraocular injection can bypass this barrier and directly inject drugs into the eye, which is the main route of administration for the treatment of eye diseases. Compared with systemic administration, it is more conducive to enrich the drug at the target site and reduce systemic adverse reactions. Intraocular administrations include intravitreal injection(IVI), suprachoroidal space(SCS)injection, subretinal injection(SRI), drug delivery systems and other invasive intraocular treatments. Previous studies have shown that different intraocular administration methods can affect the pharmacokinetic(PK)properties of drugs. This article reviews the PK changes of anti-VEGF drugs under different intraocular administration methods.
[中图分类号]
[基金项目]
南通市科技项目(No.MSZ20180)
